Olivier Querolle is a Senior Director in Medicinal Chemistry at FoRx Therapeutics, where Olivier leads various projects involving global strategy definition, compounds design, ADME planning, and data analysis and communication. Prior to their current role, Olivier held positions at NovAliX as a Drug Discovery Project Leader and at The Janssen Pharmaceutical Companies of Johnson & Johnson as a Principal Scientist. Olivier also has a background in academia, having worked as a Post-doctoral scientist at Lincoln-Nebraska University and obtaining a Ph-D in Organic and Medicinal Chemistry from University Paris XI. Their research includes the synthesis of macrocyclic analogs of Taxotere and the enantioselective total synthesis of the antibiotic A80577.
October 1, 2023 - present
January, 2023
January, 2022
Senior Director, Medicinal Chemistry at Rgenta Therapeutics
Senior Director, Medicinal Chemistry at Ambagon Therapeutics
Senior Director, Medicinal Chemistry at Rectify Pharma
Senior Director, Medicinal Chemistry at Atomwise
Senior Director, Medicinal Chemistry at Allorion Therapeutics